临床荟萃
• 专题 • 下一篇
出版日期:
发布日期:
通讯作者:
作者简介:
基金资助:
Online:
Published:
Contact:
摘要： 强直性脊柱炎(AS)是一种主要累及中轴骨骼和肌腱附着点的慢性炎症性疾病。随着对AS病因及发病 机制的研究深入,AS诊断和治疗进展迅速。传统治疗药物的规范化治疗、新型治疗药物尤其是肿瘤坏死因子α (TNF-α)抑制剂的出现,正在改写AS药物治疗历史。早期、足量、规律药物治疗和功能锻炼是迅速抑制炎症、延缓新 骨形成和影像学进展的重要方法。新型生物制剂治疗的有效性和安全性有待进一步研究证实。
关键词: 脊柱炎,强直性, 物理治疗技术, 生物制剂, 肿瘤坏死因子&alpha
Abstract:
Ankylosing spondylitis (AS) is a chronic， progressive， inflammatory disorder that mainly affects axial skeleton. Researches of the etiology and pathogenesis of AS in the past years greatly contributed to the rapid progress in diagnosis and treatment. Meanwhile， the combination of standardized use of traditional agents and TNF alpha inhibitors has rewritten the medical history of AS. Early， adequate and regular therapy and functional exercise can inhibit inflammation， delay the radiographic progression and new bone formation immediately. Further studies are required to confirm the efficacy and safety of novel biological agents.
Key words: spondylitis, ankylosing, physical therapy modalities； biological agents, tumor , necrosis , factoralpha
文琼芳,黄 烽. 强直性脊柱炎的治疗[J]. 临床荟萃, doi: 10.3969/j.issn.1004-583X.2016.05.001.
Wen Qiongfang， Huang Feng. Current treatment and future progress of ankylosing spondylitis[J]. Clinical Focus, doi: 10.3969/j.issn.1004-583X.2016.05.001.
导出引用管理器 EndNote|Ris|BibTeX
链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2016.05.001
https://huicui.hebmu.edu.cn/CN/Y2016/V31/I5/465
